Who can enter
- Children with newly diagnosed high-risk neuroblastoma who are being treated according to the SIOPEN HR-NBL-2 protocol
- Age: 1-18 years
Goal
The goal of this study is to investigate the role of specific metabolites that are released in the blood in children with high-risk neuroblastoma.
Background
Neuroblastoma cells can secrete specific metabolites that end up in the urine and blood of neuroblastoma patients. These distinct metabolites can be used to help diagnose neuroblastoma patients. Until now, we always measure the metabolites in urine. Now we want to investigate whether it is more accurate to measure these specific metabolites in blood.
Study details
Official title
International multicenter observational study to determine the diagnostic sensitivity of plasma metanephrines and urinary catecholamines and metabolites compared to standard evaluation procedures in children with high risk neuroblastoma
Cancer type
Neuroblastoma
Maximum number of patients
130, of whom 30 are expected to participate in the Netherlands.
Start date
July 15, 2022
Status
open for inclusion
Local principal investigator
Dr. G.A.M. Tytgat
Sponsor
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
Approval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO and Government of the Netherlands.
Trial registry number
Registry CCMO: NL80132.041.22
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
June 28, 2022
